These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Recent advancements in the treatment of chronic myelogenous leukemia. O'Dwyer ME; Mauro MJ; Druker BJ Annu Rev Med; 2002; 53():369-81. PubMed ID: 11818480 [TBL] [Abstract][Full Text] [Related]
5. Model mice for BCR/ABL-positive leukemias. Honda H; Hirai H Blood Cells Mol Dis; 2001; 27(1):265-78. PubMed ID: 11358387 [TBL] [Abstract][Full Text] [Related]
6. Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Clarkson B; Strife A; Wisniewski D; Lambek CL; Liu C Leukemia; 2003 Jul; 17(7):1211-62. PubMed ID: 12835715 [TBL] [Abstract][Full Text] [Related]
7. Current therapy of chronic myelogenous leukemia. Garcia-Manero G; Talpaz M; Kantarjian HM Intern Med; 2002 Apr; 41(4):254-64. PubMed ID: 11993784 [TBL] [Abstract][Full Text] [Related]
8. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Bhatia R; Munthe HA; Verfaillie CM Leukemia; 1998 Nov; 12(11):1708-17. PubMed ID: 9823945 [TBL] [Abstract][Full Text] [Related]
10. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Drexler HG; MacLeod RA; Uphoff CC Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072 [TBL] [Abstract][Full Text] [Related]
11. Allo-SCT in a rare t(8;21) evolution of CML. Hsiao HH; Tsai HJ; Liu YC; Lee CP; Lin SF Bone Marrow Transplant; 2010 Aug; 45(8):1365-6. PubMed ID: 20023710 [No Abstract] [Full Text] [Related]
12. Chronic myelogenous leukemia: biology and therapy. Gale RP; Grosveld G; Canaani E; Goldman JM Leukemia; 1993 Apr; 7(4):653-8. PubMed ID: 8464245 [TBL] [Abstract][Full Text] [Related]
13. Targeting of the BLT2 in chronic myeloid leukemia inhibits leukemia stem/progenitor cell function. Xiao M; Ai H; Li T; Rajoria P; Shahu P; Li X Biochem Biophys Res Commun; 2016 Apr; 472(4):610-6. PubMed ID: 26966074 [TBL] [Abstract][Full Text] [Related]
14. Integrin-mediated regulation of hematopoiesis: do BCR/ABL-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors? Verfaillie CM; Hurley R; Lundell BI; Zhao C; Bhatia R Acta Haematol; 1997; 97(1-2):40-52. PubMed ID: 8980609 [TBL] [Abstract][Full Text] [Related]
15. Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. Clarkson B; Strife A Leukemia; 1993 Nov; 7(11):1683-721. PubMed ID: 8231240 [TBL] [Abstract][Full Text] [Related]
16. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy. Ali MA Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498 [TBL] [Abstract][Full Text] [Related]
17. When to Consider Allogeneic Transplantation in CML. Radich J Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S93-5. PubMed ID: 27521333 [TBL] [Abstract][Full Text] [Related]
18. Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib. Morel F; Bris MJ; Herry A; Calvez GL; Marion V; Abgrall JF; Berthou C; Braekeleer MD Eur J Haematol; 2003 Apr; 70(4):235-9. PubMed ID: 12656747 [TBL] [Abstract][Full Text] [Related]
19. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]. Buchdunger E Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067 [TBL] [Abstract][Full Text] [Related]